We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
RJS College Of Pharmacy Kokamthan
In today's fast-paced world, stress has emerged as a silent epidemic affecting physical and mental well-being. It triggers complex neuroendocrine changes that can lead to anxiety, depression, insomnia, and long-term health complications. While synthetic medications exist, many people seek gentler, natural options with fewer side effects. Ashwagandha (Withania somnifera), a revered Ayurvedic adaptogen, stands out for its ability to help the body adapt to stress, lower cortisol levels, and support overall resilience. Oral dispersible tablets (ODTs) represent a modern, patient-friendly innovation. These tablets dissolve or disintegrate quickly in the mouth often within seconds without water, making them ideal for children, older adults, travelers, or anyone facing swallowing difficulties. This technology promises faster absorption and better compliance compared to traditional tablets. This review combines scientific insights on Ashwagandha’s stress-relieving properties with practical details on formulating effective ODTs. Using direct compression with superdisintegrants like crospovidone, researchers developed a promising 500 mg tablet containing 250 mg Ashwagandha extract. The optimized formulation offers rapid disintegration (~31 seconds), strong mechanical properties, high drug content, and excellent dissolution. Such herbal ODTs could provide quicker relief and greater convenience for stress management. Looking ahead, integrating nanotechnology, advanced taste-masking, and personalized approaches may further unlock the potential of these natural formulations.
Stress is the body’s natural response to demands or threats, but when it becomes chronic, it disrupts nearly every system from the heart and immune response to mood and sleep. Hans Selye famously described it as the “nonspecific response of the body to any demand.” Today, stress contributes to a wide range of issues, including hypertension, anxiety disorders, depression, and weakened immunity. The scale of the problem is staggering. According to the World Health Organization, over one billion people worldwide live with mental health conditions, with anxiety and depression among the most common. Women are often disproportionately affected, and factors like urbanization, work pressure, social media, and economic uncertainty continue to drive prevalence higher. Stress manifests in different forms: acute (short-term, like facing a deadline), chronic (ongoing, like financial strain), and episodic acute. While some stress (eustress) motivates us, distress harms health by overactivating the hypothalamic-pituitary-adrenal (HPA) axis, flooding the body with cortisol and promoting inflammation and oxidative damage.
Conventional anti-stress drugs can cause drowsiness, dependency, or cognitive fog. This has fueled interest in herbal adaptogens. Ashwagandha, often called “Indian ginseng,” has centuries of traditional use and growing modern clinical support for safely reducing stress and improving resilience. Oral dispersible tablets address practical barriers of conventional tablets such as the need for water and swallowing difficulties while offering rapid onset, making them especially suitable for stress-related conditions where quick relief and ease matter most.
1.1. Types of Stress
Stress can be classified into the following categories:
1.1.1 Acute Stress
Acute stress is a short-term response triggered by immediate threats or demanding situations. It is characterized by temporary activation of the sympathetic nervous system.
1.1.2. Chronic Stress
Chronic stress occurs when exposure to stressors becomes prolonged. It may result in hypertension, depression, anxiety disorders, insomnia, cardiovascular diseases, and immune dysfunction.
1.1.3. Episodic Acute Stress
This type involves repeated episodes of acute stress and is often associated with irritability, tension headaches, and persistent anxiety.
1.1.4. Eustress and Distress
Eustress is considered beneficial stress that motivates individuals, whereas distress is harmful and negatively affects physical and mental health.
1.2. Physiological Effects of Stress
Stress activates the hypothalamic-pituitary-adrenal (HPA) axis and stimulates secretion of cortisol and catecholamines. Persistent activation leads to oxidative stress, neuronal damage, endocrine disturbances, and impaired cognitive functions.
The major physiological effects include:
1.3. Need for Herbal Anti-Stress Formulations
Synthetic anti-anxiety and antidepressant drugs are associated with adverse effects such as sedation, dependency, withdrawal syndrome, and cognitive impairment. Herbal medicines offer safer alternatives due to their natural origin, lower toxicity, and multitarget therapeutic actions.
Ayurvedic medicinal plants have been extensively investigated for adaptogenic and anxiolytic activities. Among them, Ashwagandha has shown remarkable efficacy in reducing cortisol levels, improving cognitive performance, and enhancing stress tolerance.
1.4. Oral Dispersible Tablets
Oral dispersible tablets are solid dosage forms designed to disintegrate rapidly in saliva within seconds without water. ODTs improve patient convenience and compliance, especially among pediatric, geriatric, bedridden, psychiatric, and dysphagic patients.
1.5. Advantages of ODTs
1.6. Limitations of Conventional Tablets
Conventional tablets may exhibit delayed disintegration and swallowing difficulties. Patients experiencing stress-related disorders may suffer from dry mouth, poor compliance, and difficulty swallowing, necessitating alternative dosage forms.
1.7. Herbal Drug Delivery Systems
Herbal drug delivery systems combine traditional herbal medicines with advanced pharmaceutical technologies to improve therapeutic efficacy and patient acceptability. ODTs provide an excellent platform for delivering herbal extracts due to rapid disintegration and faster absorption.
1.8. Ashwagandha in Ayurveda
Ashwagandha (Withania somnifera) is one of the most important Rasayana herbs described in Ayurveda. It is traditionally used for rejuvenation, enhancement of vitality, memory improvement, stress reduction, and promotion of longevity.
Ancient Ayurvedic texts describe Ashwagandha as a potent adaptogen capable of strengthening the nervous system and improving resistance against stress.
2. ASHWAGANDHA PROFILE
Biological Source
Ashwagandha consists of dried roots and leaves of Withania somnifera belonging to the family Solanaceae.
Synonyms
Family
Solanaceae
Geographical Source
Ashwagandha is widely cultivated in India, Pakistan, Sri Lanka, Middle Eastern countries, and parts of Africa.
Chemical Constituents
The major active constituents of Ashwagandha include:
Withanolides
Withanolides are steroidal lactones responsible for most pharmacological activities of Ashwagandha.
Important withanolides include:
2.1. Pharmacological Activities
2.1.1. Anti-Stress Activity
Ashwagandha regulates cortisol secretion and improves stress tolerance by modulating the HPA axis.
2.1.2. Adaptogenic Activity
Adaptogens enhance the body's resistance to physical, emotional, and environmental stress.
2.1.3. Neuroprotective Activity
Ashwagandha protects neuronal cells against oxidative damage and neurodegeneration.
2.1.4. Antioxidant Activity
The herb increases endogenous antioxidant enzymes including catalase, superoxide dismutase, and glutathione peroxidase.
2.1.5. Immunomodulatory Activity
Ashwagandha stimulates immune responses and improves resistance to infections.
2.1.6. Anti-inflammatory Activity
Withanolides inhibit inflammatory mediators and reduce tissue inflammation.
2.2. Mechanism of Anti-Stress Action
Ashwagandha exerts anti-stress effects through multiple pathways:
2.3. Clinical Evidence: Multiple randomized, double-blind, placebo-controlled trials confirm benefits. Doses of 240–600 mg/day of standardized extract often reduce Perceived Stress Scale scores, anxiety ratings, and serum cortisol while improving sleep quality and well-being. Recent studies (2025–2026) further support its safety and efficacy in stressed adults, with significant improvements in psychological parameters and minimal side effects.
3. ORAL DISPERSIBLE TABLETS (ODTs)
Oral dispersible tablets (ODTs), also known as orodispersible tablets or fast-dissolving tablets, are solid dosage forms designed to disintegrate or dissolve rapidly in the oral cavity within seconds when placed on the tongue, without the need for water or chewing. The released drug is then swallowed with saliva, enabling pregastric absorption in some cases and leading to faster onset of action.
|
Aspect |
Advantages |
Disadvantages |
|
Patient Experience |
No water needed; easy for kids, elderly, travelers; pleasant mouthfeel |
May require moisture-proof packaging due to hygroscopic nature |
|
Performance |
Faster disintegration and absorption; quicker onset |
Limited high-dose drug loading; potential taste challenges with bitter herbs |
|
Compliance & Safety |
Better adherence; lower choking risk |
Tablets can be mechanically fragile if not formulated well |
|
Practicality |
Suitable for dysphagic or psychiatric patients |
Slightly higher cost due to specialized excipients |
Table 1: Advantages vs. Disadvantages of Oral Dispersible Tablets
3.1. Ideal Characteristics of ODTs
For an ODT to be successful in terms of manufacturing, patient acceptability, and therapeutic performance, it must possess several key attributes:
These characteristics ensure high patient compliance, particularly among pediatric, geriatric, dysphagic, and psychiatric patients, as well as travelers or those with busy lifestyles.
3.2. Superdisintegrants in ODTs
Superdisintegrants are specialized excipients added in small quantities (typically 2–8% w/w) that promote rapid tablet breakup in limited saliva volume. They are far more efficient than conventional disintegrants.
3.3. Common Super disintegrants and Their Mechanisms:
|
Superdisintegrant |
Mechanism of Action |
Advantages & Notes |
Typical Concentration |
|
Crospovidone |
Capillary action (wicking) + rapid swelling + strain recovery/deformation |
Excellent for ODTs; porous particles draw saliva quickly; minimal gelling; good compactability; often preferred for balance of speed and tablet strength. |
2–5% |
|
Sodium Starch Glycolate (SSG) |
High swelling capacity (up to 300 times) + wicking |
Very effective water uptake; may form viscous gel at high concentrations which can slow dissolution if not optimized. |
2–8% |
|
Croscarmellose Sodium |
Wicking + swelling (4–8 times) |
Good for both swelling and water penetration; anionic nature may interact with cationic drugs. |
2–5% |
Table 2. Overview of Common Superdisintegrants and Their Mechanisms
3.4. Additional Insights:
3.5. Preparation Methods for ODTs
Several techniques are available for manufacturing ODTs. The choice depends on the drug’s stability, dose, and desired characteristics.
3.5.1. Direct Compression (Most Preferred for Herbal Extracts) This is the simplest, most economical, and widely used method. Ingredients are blended and compressed directly into tablets without granulation or heat.
Advantages:
Limitations: Requires good flow and compressibility of the powder blend (achieved with proper excipients like mannitol and crospovidone).
3.5.2. Wet Granulation Involves binder solution to form granules, followed by drying and compression. Suitable when direct compression is not feasible due to poor flow, but not ideal for moisture-sensitive herbs.
3.5.3. Freeze Drying (Lyophilization) Produces highly porous tablets that dissolve almost instantly (e.g., Zydis technology). Offers excellent mouthfeel but is expensive and requires special equipment.
3.5.4. Spray Drying Creates porous particles with improved dissolution. Useful for taste masking and bioavailability enhancement.
3.5.5. Other Advanced Methods: Sublimation (using volatile substances to create porosity), melt granulation, phase-transition, and 3D printing (emerging for personalized dosing).
In the present study, direct compression was selected for its simplicity, cost-effectiveness, and suitability for thermolabile herbal extracts.
4. DRUG–EXCIPIENT PROFILE
|
Ingredient |
Category |
Function |
|
Ashwagandha extract |
Active ingredient |
Anti-stress adaptogen |
|
Crospovidone |
Superdisintegrant |
Rapid disintegration |
|
PVP K-30 |
Binder |
Tablet strength |
|
Mannitol |
Diluent |
Sweetness and mouthfeel |
|
Magnesium stearate |
Lubricant |
Prevent sticking |
|
Talc |
Glidant |
Improve flow |
|
Aspartame |
Sweetener |
Taste masking |
|
Flavor |
Flavoring agent |
Palatability |
Table 3. Overview of Drug- Excipients profile
4.1. Detailed Description of Excipients
5. FORMULATION TABLE
|
Ingredients |
Quantity (mg) |
|
Ashwagandha extract |
250 |
|
Crospovidone |
30 |
|
PVP K-30 |
20 |
|
Mannitol |
180 |
|
Talc |
5 |
|
Magnesium stearate |
5 |
|
Aspartame |
5 |
|
Flavor |
5 |
|
Total Weight |
500 mg |
Table 4. Formulation of Ashwagandha Oral Dispersible Tablet (500 mg)
6. METHOD OF PREPARATION
Direct Compression Method
Step 1: Sieving
All ingredients were passed through sieve no. 60 separately to remove lumps and obtain uniform particle size.
Step 2: Weighing
All ingredients were accurately weighed according to formulation requirements.
Step 3: Blending
Ashwagandha extract, mannitol, crospovidone, and PVP K-30 were blended uniformly using geometric dilution.
Step 4: Lubrication
Talc and magnesium stearate were added to the powder blend and mixed gently.
Step 5: Compression
The final blend was compressed using a rotary tablet compression machine equipped with flat-faced punches.
Step 6: Packaging
Prepared tablets were packed in aluminum blister packs to protect against moisture.
8. PREFORMULATION STUDIES
Preformulation studies were carried out to evaluate the physicochemical characteristics and flow behavior of the powder blend before compression. These studies are essential for ensuring uniformity, compressibility, manufacturability, and stability of oral dispersible tablets.
|
Parameter |
Formula |
Significance |
Ideal/Acceptable Range |
|
Angle of Repose |
Tan θ = h/r |
Determines flow properties of powder blend |
<30° indicates good flow |
|
Bulk Density |
Mass/Bulk Volume |
Indicates packing ability of powder |
Depends on formulation composition |
|
Tapped Density |
Mass/Tapped Volume |
Evaluates compressibility characteristics |
Higher than bulk density |
|
Carr’s Index |
[(Tapped Density − Bulk Density)/Tapped Density] × 100 |
Indicates compressibility and flowability |
5–15% = excellent flow; 16–20% = good flow |
|
Hausner Ratio |
Tapped Density/Bulk Density |
Determines interparticle friction |
<1.25 indicates good flow |
|
Moisture Content |
(Initial Weight − Final Weight)/Initial Weight × 100 |
Excess moisture affects stability and compressibility |
Less than 5% preferred |
Table 8.1: Preformulation Parameters and Significance
|
Study |
Procedure |
Instrument Used |
|
Angle of Repose |
Powder blend was allowed to flow through a funnel fixed at a certain height to form a cone. Height and radius were measured. |
Funnel apparatus |
|
Bulk Density |
Accurately weighed powder was transferred into a graduated cylinder and volume was recorded. |
Measuring cylinder |
|
Tapped Density |
Cylinder containing powder was tapped mechanically until constant volume was obtained. |
Bulk density apparatus |
|
Carr’s Index |
Calculated using bulk and tapped density values. |
Mathematical calculation |
|
Hausner Ratio |
Calculated using tapped density and bulk density. |
Mathematical calculation |
|
Moisture Content |
Powder sample was dried and percentage moisture loss was determined. |
Hot air oven |
Table 8.2: Experimental Procedure for Preformulation Studies
|
Parameter |
Observation |
Interpretation |
|
Angle of Repose |
27.5° ± 0.42 |
Indicates excellent flow property |
|
Bulk Density |
0.42 ± 0.01 g/cm³ |
Good packing ability |
|
Tapped Density |
0.50 ± 0.02 g/cm³ |
Suitable compressibility |
|
Carr’s Index |
16% ± 0.35 |
Good flowability |
|
Hausner Ratio |
1.19 ± 0.03 |
Low interparticle friction |
|
Moisture Content |
2.1% ± 0.11 |
Suitable for compression and stability |
Table 8.3: Observed Preformulation Results of Powder Blend
Interpretation of Preformulation Results
The precompression parameters confirmed that the prepared powder blend exhibited satisfactory flowability and compressibility suitable for direct compression technique. The angle of repose below 30° indicated excellent flow characteristics, whereas Carr’s index and Hausner ratio demonstrated acceptable compressibility behavior. Moisture content was within permissible limits, indicating good stability and reduced risk of microbial contamination.
9. EVALUATION PARAMETERS
Evaluation of oral dispersible tablets was performed to determine mechanical strength, disintegration behavior, drug release profile, and overall quality of the prepared formulation according to pharmacopeial standards.
|
Evaluation Parameter |
Method/Instrument |
Acceptance Criteria |
Significance |
|
Thickness |
Vernier calipers |
Uniform thickness |
Ensures dose uniformity and packaging suitability |
|
Hardness |
Monsanto hardness tester |
3–5 kg/cm² |
Determines mechanical strength |
|
Friability |
Roche friabilator |
Less than 1% |
Measures resistance to abrasion |
|
Weight Variation |
Digital weighing balance |
±5% IP limit |
Ensures uniformity of tablet weight |
|
Wetting Time |
Petri plate method |
Lower value preferred |
Indicates water absorption ability |
|
Disintegration Time |
USP disintegration apparatus |
Within 30–60 sec |
Determines rapid tablet dispersion |
|
Drug Content Uniformity |
UV spectrophotometer |
85–115% |
Ensures uniform drug distribution |
|
Dissolution Study |
USP Type II apparatus |
More than 85% release |
Determines drug release profile |
|
In-vitro Drug Release |
UV spectrophotometric analysis |
Rapid release desired |
Predicts therapeutic availability |
|
Stability Studies |
ICH accelerated conditions |
No significant changes |
Determines formulation stability |
Table 9.1: Evaluation Parameters of Oral Dispersible Tablets
|
Test |
Experimental Condition |
|
Thickness |
Measured using Vernier calipers on randomly selected tablets |
|
Hardness |
Determined using Monsanto hardness tester |
|
Friability |
100 revolutions at 25 rpm using Roche friabilator |
|
Weight Variation |
Twenty tablets weighed individually and average calculated |
|
Wetting Time |
Tablet placed on tissue paper soaked in water containing eosin dye |
|
Disintegration Time |
USP disintegration apparatus with distilled water at 37 ± 0.5°C |
|
Drug Content |
UV analysis at suitable λmax after dilution |
|
Dissolution Study |
USP Type II apparatus, phosphate buffer pH 6.8, 50 rpm, 37 ± 0.5°C |
|
Stability Study |
Stored at 40°C ± 2°C / 75% RH ± 5% RH for 3 months |
Table 9.2: Detailed Experimental Conditions for Evaluation Studies
10. RESULTS AND DISCUSSION
|
Parameter |
Result Obtained |
Standard Limit |
Interpretation |
|
Angle of Repose |
27.5° ± 0.42 |
<30° |
Excellent flow property |
|
Bulk Density |
0.42 ± 0.01 g/cm³ |
-- |
Good packing ability |
|
Tapped Density |
0.50 ± 0.02 g/cm³ |
-- |
Indicates suitable compressibility |
|
Carr’s Index |
16% ± 0.35 |
15–20% |
Good compressibility |
|
Hausner Ratio |
1.19 ± 0.03 |
<1.25 |
Good flowability |
|
Moisture Content |
2.1% ± 0.11 |
<5% |
Suitable for compression |
Table 10.1: Preformulation Study Results of Powder Blend
10.1. Discussion of Preformulation Results
The prepared powder blend exhibited excellent flow and compressibility characteristics suitable for direct compression. The angle of repose value below 30° confirmed free-flowing nature of the blend, which is essential for uniform die filling during tablet compression. Carr’s index and Hausner ratio values indicated low interparticle friction and satisfactory compressibility behavior. Moisture content was found within acceptable limits, suggesting reduced risk of instability and microbial growth.
|
Parameter |
Optimized Formulation (F5) |
Pharmacopoeial Limit |
Interpretation |
|
Thickness |
3.2 ± 0.05 mm |
Uniform |
Uniform tablet dimensions |
|
Hardness |
4.1 ± 0.14 kg/cm² |
3–5 kg/cm² |
Adequate mechanical strength |
|
Friability |
0.52 ± 0.03% |
<1% |
Excellent resistance to abrasion |
|
Weight Variation |
498 ± 3 mg |
±5% |
Uniform tablet weight |
|
Wetting Time |
24 ± 1.2 sec |
Low value preferred |
Rapid water penetration |
|
Disintegration Time |
31 ± 2.1 sec |
<60 sec |
Rapid tablet disintegration |
|
Drug Content Uniformity |
98.7 ± 0.45% |
85–115% |
Uniform drug distribution |
|
Drug Release at 10 min |
72.3 ± 1.5% |
-- |
Rapid initial release |
|
Drug Release at 20 min |
88.6 ± 1.8% |
-- |
Enhanced dissolution profile |
|
Drug Release at 30 min |
96.4 ± 1.4% |
>85% |
Excellent drug release |
Table 10.2: Evaluation Results of Ashwagandha Oral Dispersible Tablets
The optimized formulation was subjected to accelerated stability testing under ICH recommended conditions to evaluate physical stability, drug content retention, and dissolution behavior over a period of three months.
|
Parameter |
Initial |
After 1 Month |
After 2 Months |
After 3 Months |
|
Appearance |
Uniform |
Uniform |
Uniform |
Uniform |
|
Hardness (kg/cm²) |
4.1 |
4.0 |
4.0 |
3.9 |
|
Friability (%) |
0.52 |
0.55 |
0.57 |
0.59 |
|
Disintegration Time (sec) |
31 |
32 |
33 |
34 |
|
Drug Content (%) |
98.7 |
98.2 |
97.8 |
97.4 |
|
Drug Release at 30 min (%) |
96.4 |
95.9 |
95.4 |
95.1 |
Table 10.3: Accelerated Stability Study Results of Optimized Formulation (ICH Guidelines)
10.2. Comparative Discussion of Results
The optimized Ashwagandha oral dispersible tablet formulation demonstrated satisfactory physicochemical properties and complied with pharmacopeial requirements. The presence of crospovidone significantly enhanced tablet disintegration through rapid capillary action and swelling mechanism. Mannitol improved mouthfeel and imparted a pleasant cooling sensation, thereby increasing patient acceptability.
The hardness value indicated sufficient mechanical integrity to withstand handling during packaging and transportation. Friability below 1% confirmed excellent tablet durability. Wetting and disintegration times were considerably low, demonstrating efficient saliva penetration and rapid tablet breakup.
Dissolution studies showed more than 96% drug release within 30 minutes, indicating rapid availability of active phytoconstituents for therapeutic action. Accelerated stability studies conducted according to ICH guidelines demonstrated that the formulation remained stable with no significant changes in physical appearance, drug content, or dissolution profile.
Overall, the developed Ashwagandha oral dispersible tablets exhibited rapid disintegration, excellent stability, satisfactory mechanical properties, and enhanced patient convenience. The formulation may serve as an effective herbal dosage form for stress management with improved patient compliance compared to conventional tablets.
11. FUTURE PROSPECTS
Herbal ODTs, particularly Ashwagandha-based, hold substantial commercial and therapeutic promise amid rising demand for natural stress remedies. The global Ashwagandha market is expanding rapidly due to consumer preference for adaptogens.
Key Future Directions:
These advancements could position Ashwagandha ODTs as a mainstream, evidence-based option in preventive and therapeutic stress management.
CONCLUSION
Stress has emerged as one of the most pressing public health challenges of the 21st century, significantly affecting the quality of life across all age groups. Conventional synthetic anti-stress medications, although effective, are often associated with undesirable side effects such as sedation, dependency, and cognitive impairment. In this context, herbal adaptogens like Ashwagandha (Withania somnifera) offer a promising natural alternative due to their proven ability to modulate the HPA axis, reduce cortisol levels, exert anxiolytic and neuroprotective effects, and improve overall resilience with an excellent safety profile.
The successful formulation and evaluation of Ashwagandha Oral Dispersible Tablets (ODTs) represent a meaningful advancement in herbal drug delivery. By incorporating 250 mg of standardized Ashwagandha extract into a 500 mg tablet using the direct compression technique with crospovidone as a superdisintegrant, the optimized formulation achieved rapid disintegration (31 seconds), optimal hardness (4.1 kg/cm²), low friability (0.52%), high drug content uniformity (98.7%), and excellent dissolution (96.4% within 30 minutes). These attributes effectively overcome the limitations of conventional tablets, such as swallowing difficulties and delayed onset of action, while significantly enhancing patient compliance and therapeutic effectiveness.
This patient-centric dosage form is particularly beneficial for pediatric, geriatric, dysphagic, and busy individuals who require convenient, water-free administration with rapid onset of anti-stress benefits. The use of mannitol and suitable taste-masking agents further improves palatability, addressing the inherent bitterness of herbal extracts.
In conclusion, the developed Ashwagandha ODTs successfully bridge traditional Ayurvedic wisdom with modern pharmaceutical technology. They offer a safe, effective, convenient, and rapid-acting herbal solution for stress management. As the demand for evidence-based natural therapies continues to rise globally, Ashwagandha ODTs hold substantial therapeutic and commercial potential.
Future research focusing on large-scale clinical trials, bioavailability enhancement through nanotechnology, advanced taste-masking strategies, and long-term stability studies will further strengthen the position of these formulations in mainstream healthcare. Ultimately, Ashwagandha-based oral dispersible tablets have the potential to become a preferred choice for holistic stress management, contributing meaningfully to global mental health and wellness.
REFERENCES
Sairam Dilip Tambe*, Chaudhari Kaweri K., A review article on : Anti- anxiety activity, Int. J. Sci. R. Tech., 2026, 3 (5), 1064-1078. https://doi.org/10.5281/zenodo.20428047
10.5281/zenodo.20428047